Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
1. A pharmaceutical combination comprising chemotherapeutic agents, wherein said chemotherapeutic agents consist of
1) regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt, or a polymorph thereof and
2) nivolumab,
wherein the regorafenib metabolite is selected from the group consisting of:
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide I-oxide,
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-(hydroxymethyl)pyridine-2-carboxamide,
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxamide and
4-[4-({[4-chloro-3(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxamide I-oxide and
wherein said chemotherapeutic agents are separate from one another.
2. The combination of claim 1 which is a combination pack.
3. The combination of claim 1 wherein said chemotherapeutic agents are in separate dosage forms for administration simultaneously or sequentially for use in the treatment of the same disease in a subject.
4. The combination of claim 3 for sequential administration wherein a regorafenib dosage form is for administration first followed by the administration of a nivolumab dosage form.
5. The combination of claim 1 wherein regorafenib is in an oral dosage form and nivolumab is in an intravenous dosage form.
6. The combination of claim 1 wherein regorafenib is in a dosage form in an amount of 10 to 100 mg.
7. The combination of claim 1 with combined dosages for treating malignant disorders and pre-malignant hyper-proliferative disorders.
8. The combination of claim 1 with combined dosages for treating hyper-proliferative disorders wherein the hyper-proliferative disorders are selected from the group consisting of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
9. The combination of claim 8 wherein the hyper-proliferative disorders are selected from the group consisting of hepatic cell cancer, colorectal cancer and gastrointestinal stromal tumors (GIST).
10. The combination of claim 8 wherein the hyper-proliferative disorder is hepatic cell cancer.
11. The combination of claim 8 wherein the hyper-proliferative disorder is colorectal cancer.
12. A method of treating malignant disorders and pre-malignant hyper-proliferative disorders in a subject in need thereof comprising administering chemotherapeutic agents, wherein said chemotherapeutic agents are separate from one another and consist of effective amounts of
1) regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt, or a polymorph thereof and
2) nivolumab,
wherein the regorafenib metabolite is selected from the group consisting of:
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide I-oxide,
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-(hydroxymethyl)pyridine-2-carboxamide,
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]1pyridine-2-carboxamide and
4-[4-({[4-chloro-3(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]1pyridine-2-carboxamide I-oxide.
13. The method of claim 12 wherein regorafenib is administered first followed by the administration of nivolumab.
14. The method of claim 12 wherein regorafenib is administered orally and nivolumab is administered intravenously.
15. The method of claim 12 wherein regorafenib is administered in the form of a tablet and nivolumab is administered intravenously.
16. A method of treating hyper-proliferative disorders in a subject in need thereof comprising administering chemotherapeutic agents, wherein said chemotherapeutic agents are separate from one another and consist of effective amounts of
1) regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt, or a polymorph thereof and
2) nivolumab,
wherein the hyper-proliferative disorders are selected from the group consisting of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
17. The method of claim 16 wherein said chemotherapeutic agents consist of effective amounts of
1) regorafenib and
2) nivolumab,
wherein the hyper-proliferative disorders are selected from the group consisting of hepatic cell cancer, colorectal cancer and gastrointestinal stromal tumors (GIST).
18. The method of claim 17 wherein regorafenib is administered in the form of a tablet and nivolumab is administered intravenously.
19. The method of claim 16 wherein the hyper-proliferative disorder is hepatic cell cancer.
20. The method of claim 16 wherein the hyper-proliferative disorder is colorectal cancer.
21. The method of claim 16 wherein regorafenib is administered first followed by the administration of nivolumab.
22. The method of claim 16 wherein regorafenib is administered orally and nivolumab is administered intravenously.
23. A pharmaceutical combination comprising separate chemotherapeutic agents, wherein said chemotherapeutic agents consist of
1) regorafenib and
2) nivolumab.
24. The combination of claim 23 wherein regorafenib is in the form of a tablet in an amount of 10 to 100 mg and nivolumab is in an intravenous dosage form.